- Home
- SON vs WGS Comparison
SON vs WGS Comparison
Compare SON & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SON | WGS |
|---|---|---|
| Founded | 1899 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SON | WGS |
|---|---|---|
| Price | $48.96 | $94.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $54.00 | ★ $138.13 |
| AVG Volume (30 Days) | ★ 964.3K | 731.2K |
| Earning Date | 02-16-2026 | 02-23-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | ★ 116.52 | N/A |
| EPS | ★ 6.30 | 0.07 |
| Revenue | ★ $7,114,053,000.00 | $402,190,000.00 |
| Revenue This Year | $44.72 | $41.17 |
| Revenue Next Year | N/A | $23.94 |
| P/E Ratio | ★ $7.66 | $1,346.36 |
| Revenue Growth | ★ 67.86 | 50.50 |
| 52 Week Low | $38.65 | $55.17 |
| 52 Week High | $50.09 | $170.87 |
Technical Indicators
Market Signals| Indicator | SON | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 65.60 | 30.38 |
| Support Level | $47.00 | $91.65 |
| Resistance Level | $49.12 | $106.76 |
| Average True Range (ATR) | 1.00 | 6.78 |
| MACD | -0.18 | -0.07 |
| Stochastic Oscillator | 73.24 | 14.13 |
Price Performance
Historical ComparisonAbout SON Sonoco Products Company
Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.